Blum, William <br/><br/>
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.  [electronic resource] 

 -  Proceedings of the National Academy of Sciences of the United States of America  Apr 2010 
 - 7473-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1091-6490 
<br/><br/><label>Standard No.: </label>10.1073/pnas.1002650107  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Antimetabolites, Antineoplastic--therapeutic use<br/>Azacitidine--analogs & derivatives<br/>Cohort Studies<br/>DNA Methylation<br/>Decitabine<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Karyotyping<br/>Leukemia, Myeloid, Acute--metabolism<br/>Male<br/>MicroRNAs--biosynthesis<br/>Middle Aged<br/>Remission Induction<br/>Treatment Outcome